# Metronomic Therapy in Patients With Metastatic Melanoma

> **NCT01542255** · PHASE2 · TERMINATED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** vinblastine
- **DRUG:** Cyclophosphamide
- **DRUG:** dacarbazine

## Key facts

- **NCT ID:** NCT01542255
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low accrual not allowing to support statistical endpoints
- **Last updated:** 2019-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542255, "Metronomic Therapy in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01542255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*